General Information of DTT (ID: TT7M3PI)

DTT Name Ribosomal protein S6 kinase (S6K) DTT Info
Gene Name S6K

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
4 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY-2584702 DML8M3B Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
LY2780301 DM93AJW Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
LYS-6KAKT1 DMLXGAI Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
XL418 DME0F5W Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
------------------------------------------------------------------------------------
1 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27410995-Compound-Figure3k DMJ0QLB N. A. N. A. Patented [5]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84.
2 A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.
3 DOI: 10.1016/S1359-6349(10)71767-5
4 Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer
5 Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78.